Incyte to Develop MacroGenics' Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab

Incyte will partner with MacroGenics to develop its Phase I cancer immunotherapy candidate MGA012, a monoclonal antibody designed to inhibit programmed cell death protein 1 (PD-1), through a collaboration that could generate up to $900 million-plus for MacroGenics, the companies said today.Incyte has acquired exclusive worldwide rights to develop and commercialize MGA012 in all indications. The companies’ global collaboration and licensing agreement also gives MacroGenics the right to deve